Streetbeat News

Stock Prices

AVGO

Financial giants have shown a bearish sentiment towards Broadcom (NASDAQ:AVGO) through options trading. Analysis reveals 53% bearish and 33% bullish trades, with significant put and call options activity. Broadcom's current market position shows a slight decline, with analysts maintaining positive ratings and high price targets.

Portfolio Pulse from Benzinga Insights

August 14, 2024 | 2:01 pm

INTA

Intapp (NASDAQ: INTA) has been analyzed by 4 analysts, showing a range of sentiments from bullish to somewhat bullish. The average 12-month price target is $48.5, with a high of $50.00 and a low of $46.00. Recent actions include UBS raising its target to $50.00 and B of A Securities lowering it to $48.00. Intapp has shown a revenue growth rate of 20.23% and maintains strong financial health with efficient cost management and a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

August 14, 2024 | 2:01 pm

THC

Analysts' ratings for Tenet Healthcare (NYSE:THC) over the last quarter vary from bullish to bearish, with 17 analysts providing insights. The average 12-month price target is $155.59, reflecting a 14.78% increase from the previous target. Analysts from firms like UBS, Goldman Sachs, and Wells Fargo have raised their price targets, indicating positive sentiment. Tenet Healthcare has shown positive revenue growth and strong financial health, but faces challenges in debt management.

Portfolio Pulse from Benzinga Insights

August 14, 2024 | 2:00 pm

CRBU

Analysts' ratings for Caribou Biosciences (NASDAQ:CRBU) vary from bullish to somewhat bullish, with 3 out of 4 analysts giving a bullish rating. The average 12-month price target has dropped by 26.79% to $10.25. The company's financials show a decline in revenue and a high net margin, but strong ROE and ROA. Debt management is also favorable.

Portfolio Pulse from Benzinga Insights

August 14, 2024 | 2:00 pm

VRCA

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) released preliminary results from Part 2 of its Phase 2 trial of VP-315 for basal cell carcinoma. The results showed no dose-limiting toxicities, with 51% of lesions achieving complete histologic clearance. Despite the positive data, VRCA stock fell 24.10% to $4.01.

Portfolio Pulse from Vandana Singh

August 14, 2024 | 1:52 pm

FMQQ

IPO

NU

Nu Holdings Ltd. (NYSE:NU) reported strong Q2 financial results, adding 5.2 million customers and achieving a 28% return on equity. Despite currency headwinds in Latin America, the stock has gained over 60% in the past year. Investors can gain exposure via Renaissance IPO ETF (NYSE:IPO) and FMQQ The Next Frontier Internet ETF (NYSE:FMQQ).

Portfolio Pulse from Nabaparna Bhattacharya

August 14, 2024 | 1:50 pm

COIN

JPM

Balaji Srinivasan, former CTO of Coinbase, claims the true US debt is $175 trillion, far exceeding the official $35 trillion figure. This includes entitlements like Social Security and Medicare. The Federal Reserve has made more emergency loans in 2023 than during the COVID-19 pandemic and 2008 financial crisis. Interest payments are now the second-largest government expense. Major economies are moving away from the US dollar, with China, Russia, and India increasing gold reserves. Government officials like Fed Chair Jerome Powell and Treasury Secretary Janet Yellen believe current debt levels are manageable, but others, including JPMorgan CEO Jamie Dimon, warn of potential risks.

Portfolio Pulse from Natan Ponieman

August 14, 2024 | 1:48 pm

GNPX

Genprex has decided to cease enrollment in the Acclaim-2 clinical trial due to difficulties in recruiting patients, citing competition from numerous other trials. Additionally, the company is limiting the Acclaim-1 trial to a single cohort due to resource prioritization, reducing the potential breadth of the study.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 1:46 pm

PYCR

Top Wall Street analysts have updated their price targets for Paycor HCM (NASDAQ:PYCR) ahead of its Q4 earnings release on August 14. Analysts expect earnings of 9 cents per share and revenue of $161.17 million. Recent ratings include Buy, Neutral, and Market Perform, with price targets ranging from $14 to $22.

Portfolio Pulse from Avi Kapoor

August 14, 2024 | 1:45 pm

IMCC

IM Cannabis Corp. (NASDAQ:IMCC) reported a 12% YoY increase in Q2 revenue to CA$14.8 million, driven by a 200% surge in German sales post-legalization. Despite the revenue growth, the company faced a significant drop in gross profit and an increased EBITDA loss. A share consolidation plan was also announced to attract institutional investors.

Portfolio Pulse from Jelena Martinovic

August 14, 2024 | 1:43 pm